Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.54 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14921899 | 0.86 | SCN9A (0.54) | SCN9A | |
| SCHEMBL16172456 | 0.85 | SCN9A (0.41) | SCN9AFPR2SCN4A | |
| SCHEMBL16172496 | 0.82 | MAPT (0.39) | SCN9AFPR2SCN4A | |
| SCHEMBL16172472 | 0.80 | SCN9A (0.51) | SCN9A | |
| SCHEMBL16164032 | 0.79 | SCN9A (0.57) | SCN9AFPR2 | |
| SCHEMBL14934307 | 0.78 | SCN9A (0.58) | SCN9A | |
| SCHEMBL16172522 | 0.78 | SCN9A (0.43) | SCN9AFPR2 | |
| SCHEMBL16172476 | 0.77 | SCN9A (0.43) | SCN9AFPR2SCN4A | |
| SCHEMBL14919880 | 0.75 | SCN9A (0.64) | SCN9AFPR2DHODH | |
| SCHEMBL14920119 | 0.74 | SCN9A (0.62) | SCN9AFPR2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2013064884-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | CACNA1A, SCN1B, SCN1A | SCN9A 23/4885FPR2 1434/4885SCN4A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.